Neuropathy and Serum Vitamin B 12 Level in Metformin Treated Type2 Diabetic Patients of North India: A Single Centre Observational Study

Abstract

Abstract: Aim: To determine the prevalence of neuropathy with the help of MNSI questionnaire (Michigan neuropathy screening instrument) Method: A single Centre observational study was completed in a tertiary care hospital between jan 2020 to april 2021. .In our study, 95 type 2 diabetes patients who had been taking metformin for a minimum of three months were included in a row. The severity of peripheral neuropathy (as measured by MNSI) and severe characteristics were compared. The length of diabetes, the length of metformin medication, dietary history, and HbA1c levels were some of these. B12 15 pg/ml was considered a definitive B12 deficit, while 220pg/ml was considered a potential B12 insufficiency. Result: In our research, we discovered a weak negative relationship (r=0.19) between the duration of metformin administration and vitamin B12 levels. In our investigation, the average vitamin B12 concentration was 99.22 pg/mL. Peripheral neuropathy and metformin medication duration had a favourable connection (r=1). The typical MNSI result was 11.2. Patients without peripheral neuropathy took metformin for an average of 3.5 years, whereas those with the condition took the drug for an average of 8.04 years.